Characterization of Acute HCV Infection and Transmission Networks in People Who Currently Inject Drugs in Catalonia: Usefulness of Dried Blood Spots.
Adolescent
Adult
Cross-Sectional Studies
Dried Blood Spot Testing
Female
Genotyping Techniques
Harm Reduction
Hepacivirus
/ genetics
Hepatitis C
/ blood
High-Throughput Nucleotide Sequencing
Humans
Male
Phylogeny
Spain
Substance Abuse, Intravenous
/ complications
Viral Nonstructural Proteins
/ genetics
Viremia
/ diagnosis
Young Adult
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
13
01
2021
received:
15
06
2020
accepted:
20
01
2021
pubmed:
21
2
2021
medline:
6
1
2022
entrez:
20
2
2021
Statut:
ppublish
Résumé
Accurate identification of recent HCV infections is critical for tracing the extent and mechanisms of ongoing transmission. We aimed to validate dried blood spot (DBS) samples for the assessment of Hepatitis C virus (HCV) genetic diversity and to determine epidemiological parameters including incidence, determinants of acute infection, and phylogenetic clustering in people who inject drugs (PWID). HCV nonstructural protein 5B next-generation sequencing was performed from plasma and/or DBS in 220 viremic PWID from the HepCdetect II study. No significant differences were found in consensus sequences or Shannon entropy (SE) intrahost diversity estimate between paired plasma/DBS specimens. SE values were used to identify acute infections with 93.3% sensitivity (95% CI, 0.81-1.06) and 95.0% specificity (95% CI, 0.88-1.02) in a set of well-defined controls. An acute HCV infection (either primary infection or reinfection) was detected in 13.5% of viremic participants and was associated with age ≤30 years (OR, 8.09), injecting less than daily (OR, 4.35), ≤5 years of injected drug use (OR, 3.43), sharing cocaine snorting straws (OR, 2.89), and being unaware of their HCV status (OR, 3.62). Annualized HCV incidence was estimated between 31 and 59/100 person-years. On phylogenetic analysis, 46.8% of viremic cases were part of a transmission pair or cluster; age ≤30 years (OR, 6.16), acute infection (OR, 5.73), and infection with subtype 1a (OR, 4.78) were independently associated with this condition. The results obtained from plasma and DBS characterize PWID with acute infection and those involved in ongoing HCV transmission and allow estimating incidence from cross-sectional data. This information is critical for the design and assessment of targeted harm reduction programs and test-and-treat interventions and to facilitate monitoring of HCV elimination in this key population.
Sections du résumé
BACKGROUND AND AIMS
Accurate identification of recent HCV infections is critical for tracing the extent and mechanisms of ongoing transmission. We aimed to validate dried blood spot (DBS) samples for the assessment of Hepatitis C virus (HCV) genetic diversity and to determine epidemiological parameters including incidence, determinants of acute infection, and phylogenetic clustering in people who inject drugs (PWID).
APPROACH AND RESULTS
HCV nonstructural protein 5B next-generation sequencing was performed from plasma and/or DBS in 220 viremic PWID from the HepCdetect II study. No significant differences were found in consensus sequences or Shannon entropy (SE) intrahost diversity estimate between paired plasma/DBS specimens. SE values were used to identify acute infections with 93.3% sensitivity (95% CI, 0.81-1.06) and 95.0% specificity (95% CI, 0.88-1.02) in a set of well-defined controls. An acute HCV infection (either primary infection or reinfection) was detected in 13.5% of viremic participants and was associated with age ≤30 years (OR, 8.09), injecting less than daily (OR, 4.35), ≤5 years of injected drug use (OR, 3.43), sharing cocaine snorting straws (OR, 2.89), and being unaware of their HCV status (OR, 3.62). Annualized HCV incidence was estimated between 31 and 59/100 person-years. On phylogenetic analysis, 46.8% of viremic cases were part of a transmission pair or cluster; age ≤30 years (OR, 6.16), acute infection (OR, 5.73), and infection with subtype 1a (OR, 4.78) were independently associated with this condition.
CONCLUSIONS
The results obtained from plasma and DBS characterize PWID with acute infection and those involved in ongoing HCV transmission and allow estimating incidence from cross-sectional data. This information is critical for the design and assessment of targeted harm reduction programs and test-and-treat interventions and to facilitate monitoring of HCV elimination in this key population.
Identifiants
pubmed: 33609288
doi: 10.1002/hep.31757
pii: 01515467-202108000-00007
doi:
Substances chimiques
Viral Nonstructural Proteins
0
NS-5 protein, hepatitis C virus
EC 2.7.7.48
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
591-606Informations de copyright
© 2021 by the American Association for the Study of Liver Diseases.
Références
Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, et al. Global, regional, and country‐level estimates of hepatitis C infection among people who have recently injected drugs. Addiction 2019;114:150‐166.
European Centre for Disease Prevention and Control . Hepatitis C. In: ECDC. Annual Epidemiological Report for 2017. Stockholm: ECDC; 2019.
Barbosa C, Fraser H, Hoerger TJ, Leib A, Havens JR, Young A, et al. Cost‐effectiveness of scaling‐up HCV prevention and treatment in the United States for people who inject drugs. Addiction 2019;114:2267‐2278.
Pawlotsky J‐M, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 2018;69:461‐511.
Chung RT, Ghany MG, Kim AY, Marks KM, Naggie S, Vargas HE, et al. Hepatitis C guidance 2018 update: AASLD‐IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 2018;67:1477‐1492.
European Centre for Disease Prevention and Control. Hepatitis C . Monitoring the Elimination of Viral Hepatitis as a Public Health Threat Among People Who Inject Drugs in Europe: The Elimination Barometer. Technical Reports. Luxembourg: ECDC; 2019.
World Health Organization . Global Health Sector Strategy on Viral Hepatitis 2016‐2021. Geneva, Switzerland: WHO; 2016.
World Health Organization . Guidelines on Hepatitis B and C Testing. Geneva, Switzerland: WHO; 2017.
Grebely J, Applegate TL, Cunningham P, Feld JJ. Hepatitis C point‐of‐care diagnostics: in search of a single visit diagnosis. Expert Rev Mol Diagn 2017;17:1109‐1115.
Chevaliez S, Wlassow M, Volant J, Roudot‐Thoraval F, Bachelard A, Poiteau L, et al. Assessing molecular point‐of‐care testing and dried blood spot for hepatitis C virus screening in people who inject drugs. Open Forum Infect Dis 2020;7:ofaa196.
Lange B, Roberts T, Cohn J, Greenman J, Camp J, Ishizaki A, et al. Diagnostic accuracy of detection and quantification of HBV‐DNA and HCV RNA using dried blood spot (DBS) samples—a systematic review and meta‐analysis. BMC Infect Dis 2017;17:693.
Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, et al. Research priorities to achieve universal access to hepatitis C prevention, management and direct‐acting antiviral treatment among people who inject drugs. Int J Drug Policy 2017;47:51‐60.
Saludes V, Antuori A, Folch C, González N, Ibáñez N, Majó X, et al. Utility of a one‐step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia. Int JDrug Policy 2019;74:236‐245.
Olmstead AD, Joy JB, Montoya V, Luo I, Poon AFY, Jacka B, et al. A molecular phylogenetics‐based approach for identifying recent hepatitis C virus transmission events. Infect Genet Evol 2015;33:101‐109.
Martinello M, Hajarizadeh B, Grebely J, Dore GJ, Matthews GV. Management of acute HCV infection in the era of direct‐acting antiviral therapy. Nat Rev Gastroenterol Hepatol 2018;15:412‐424.
Montoya V, Olmstead AD, Janjua NZ, Tang P, Grebely J, Cook D, et al. Differentiation of acute from chronic hepatitis C virus infection by nonstructural 5B deep sequencing: a population‐level tool for incidence estimation. Hepatology 2015;61:1842‐1850.
Montoya V, Olmstead A, Tang P, Cook D, Janjua N, Grebely J, et al. Deep sequencing increases hepatitis C virus phylogenetic cluster detection compared to Sanger sequencing. Infect Genet Evol 2016;43:329‐337.
Jacka B, Applegate T, Poon AF, Raghwani J, Harrigan PR, DeBeck K, et al. Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada. J Hepatol 2016;64:1247‐1255.
Sacks‐Davis R, Daraganova G, Aitken C, Higgs P, Tracy L, Bowden S, et al. Hepatitis C virus phylogenetic clustering is associated with the social‐injecting network in a cohort of people who inject drugs. PLoS One 2012;7:e47335.
Jacka B, Applegate T, Krajden M, Olmstead A, Harrigan PR, Marshall BDL, et al. Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada. Hepatology 2014;60:1571‐1580.
Saludes V, Folch C, Morales‐Carmona A, Ferrer L, Fernàndez‐López L, Muñoz R, et al. Community‐based screening of hepatitis C with a one‐step RNA detection algorithm from dried‐blood spots: analysis of key populations in Barcelona, Spain. J Viral Hepat 2018;25:236‐244.
Murphy DG, Willems B, Deschenes M, Hilzenrat N, Mousseau R, Sabbah S. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′ untranslated region sequences. J Clin Microbiol 2007;45:1102‐1112.
Saludes V, Antuori A, Reinhardt B, Viciana I, Clavijo E, Schreiber L, et al. Reliable resolution of ambiguous hepatitis C virus genotype 1 results with the Abbott HCV Genotype Plus RUO assay. Sci Rep 2019;9:3678.
Li H, Durbin R. Fast and accurate short read alignment with Burrows‐Wheeler transform. Bioinformatics 2009;25:1754‐1760.
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics 2009;25:2078‐2079.
Hope VD, Hickman M, Ngui SL, Jones S, Telfer M, Bizzarri M, et al. Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. J. Viral Hepat 2011;18:262‐270.
Price MN, Dehal PS, Arkin AP. FastTree 2—approximately maximum‐likelihood trees for large alignments. PLoS One 2010;5:e9490.
Lamoury FMJ, Jacka B, Bartlett S, Bull RA, Wong A, Amin J, et al. The influence of hepatitis C virus genetic region on phylogenetic clustering analysis. PLoS One 2015;10:e0131437.
Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol 2013;30:2725‐2729.
Tuaillon E, Mondain A‐M, Meroueh F, Ottomani L, Picot M‐C, Nagot N, et al. Dried blood spot for hepatitis C virus serology and molecular testing. Hepatology 2010;51:752‐758.
Olmstead AD, Montoya V, Chui CK, Dong W, Joy JB, Tai V, et al. A systematic, deep sequencing‐based methodology for identification of mixed‐genotype hepatitis C virus infections. Infect Genet Evol 2019;69:76‐84.
Quer J, Gregori J, Rodríguez‐Frias F, Buti M, Madejon A, Perez‐del‐Pulgar S, et al. High‐resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods. J Clin Microbiol 2015;53:219‐226.
Aguilera A, Navarro D, Rodríguez‐Frias F, Viciana I, Martínez‐Sapiña AM, Rodríguez MJ, et al. Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000‐2015 period (the GEHEP 005 study). J Viral Hepat 2017;24:725‐732.
Robaeys G, Bielen R, Azar DG, Razavi H, Nevens F. Global genotype distribution of hepatitis C viral infection among people who inject drugs. J Hepatol 2016;65:1094‐1103.
McMahon BJ, Bruden D, Townshend‐Bulson L, Simons B, Spradling P, Livingston S, et al. Infection with hepatitis C virus genotype 3 is an independent risk factor for end‐stage liver disease, hepatocellular carcinoma, and liver‐related death. Clin Gastroenterol Hepatol 2017;15:431‐437.e2.
Falade‐Nwulia O, Suarez‐Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct‐acting agent therapy for hepatitis C virus infection. Ann Intern Med 2017;166:637.
Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct‐acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta‐analysis. Lancet Gastroenterol Hepatol 2018;3:754‐767.
Cunningham EB, Amin J, Feld JJ, Bruneau J, Dalgard O, Powis J, et al. Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study. Int J Drug Policy 2018;62:14‐23.
Boon D, Bruce V, Patel EU, Quinn J, Srikrishnan AK, Shanmugam S, et al. Antibody avidity‐based approach to estimate population‐level incidence of hepatitis C. J Hepatol 2020;73:294‐302.
Vallejo F, Barrio G, Brugal MT, Pulido J, Toro C, Sordo L, et al. High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes. J Epidemiol Community Health 2015;69:599‐603.
Morris MD, Shiboski S, Bruneau J, Hahn JA, Hellard M, Prins M, et al. Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: the InC3 collaboration. Clin Infect Dis 2017;64:860‐869.
Lens S, Miralpeix A, Galvez M, Martro E, Gonzalez N, Rodriguez‐Tajes S, et al. Externalized HCV linkage‐to‐care cascade in the biggest harm reduction center in Barcelona: approaching a high‐risk PWID population [Abstract]. J Hepatol 2020;73:S360.
Mittal ML, Jain S, Sun S, DeBeck K, Milloy MJ, Hayashi K, et al. Opioid agonist treatment and the process of injection drug use initiation. Drug Alcohol Depend 2019;197:354‐360.
Baluku M, Wamala T. When and how do individuals transition from regular drug use to injection drug use in Uganda? Findings from a rapid assessment. Harm Reduct J 2019;16:73.
Aaron S, McMahon JM, Milano D, Torres L, Clatts M, Tortu S, et al. Intranasal transmission of hepatitis C virus: virological and clinical evidence. Clin Infect Dis 2008;47:931‐934.
Hunt PG, Mathew SN. Preventing and curtailing injecting drug use: a review of opportunities for developing and delivering “route transition interventions.” Drug Alcohol Rev 1999;18:441‐451.
Folch C, Casabona J, Espelt A, Majó X, Meroño M, Gonzalez V, et al. High prevalence and incidence of HIV and HCV among new injecting drug users with a large proportion of migrants—is prevention failing? Subst Use Misuse 2016;51:250‐260.
Bruneau J, Zang G, Abrahamowicz M, Jutras‐Aswad D, Daniel M, Roy É. Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study. Clin Infect Dis 2014;58:755‐761.
Saludes V, Antuori A, Lazarus JV, Folch C, González‐Gómez S, González N, et al. Evaluation of the Xpert HCV VL Fingerstick point‐of‐care assay and dried blood spot HCV RNA testing as simplified diagnostic strategies among people who inject drugs in Catalonia, Spain. Int J Drug Policy 2020;80:102734.
Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, et al. Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study. PLoS One 2015;10:e0122232.